FDA Expands ImmunityBio's Anktiva Label for Bladder Cancer Treatment

Key Facts

1The FDA approved an expanded label for ImmunityBio's Anktiva to include all patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

The FDA approved an expanded label for ImmunityBio's drug Anktiva to include all patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Zacks reported that this expansion removes previous limitations on which NMIBC patients could receive the treatment combination.

IBRX closed at $9.91 on October 14, 2026, with the stock reaching a day high of $10.46 and a low of $9.35 during that session. The broader label is expected to increase the commercial opportunity and revenue potential for the biotechnology firm by expanding its addressable market.